# Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function

> **NCT00652626** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 31 (actual)

## Conditions studied

- MDS
- AML
- Solid Tumors
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
- Hodgkin's Disease

## Interventions

- **DRUG:** azacitidine

## Key facts

- **NCT ID:** NCT00652626
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11-01
- **Primary completion:** 2012-07-01
- **Final completion:** 2012-07-01
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2019-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00652626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00652626, "Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00652626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*